European guidelines aspirin
Summary of European guidelines for aspirin
- “Patients with DM and symptomatic CVD should be treated no differently to patients without DM
- In patients with DM at moderate CV risk, aspirin for primary prevention is not recommended
- In patients with DM at high/very high risk, aspirin may be considered in primary prevention
- Type 1 diabetes and CVD prevention [in vivo platelet activation has been reported]
- Body mass and antiplatelet responsiveness especially in those with diabetes and obesity where higher dose strategies need investigation
- Are antithrombotic effects similar in pre-DM and DM?

Source 2016 European guidelines for cardiovascular disease prevention
For further information please see the full guidance at:
Primary prevention of cancer
There is a European Code Against Cancer code which covers healthy lifestyle, work place safety, vaccination programmes and cancer screening.
https://cancer-code-europe.iarc.fr/index.php/en/
Aspirin and pre-eclampsia
The International Federation of Gynecology and Obstetrics recommend that women identified as high risk of pre-eclampsia during first trimester screening should be given aspirin prophylaxis (150mg at night from 11-14 weeks gestation until delivery or the diagnosis of pre-eclampsia). They do not advocate a policy of low-dose aspirin for all pregnant women.
Poon LC, Shennan A, Hyett JA et al The International federation of gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: a pragmatic guide for first-trimester screening and prevention. Int J Gynecol Obstet 2019; 145 (Suppl.1) 1-33. @
https://obgyn.onlinelibrary.wiley.com/doi/epdf/10.1002/ijgo.12802